Sign Up for Keystone Heart Updates
EU
US
September 29, 2020 TCT Connect 2020
TCT Connect 2020
by TCT Connect 2020
246 people viewed this event.
Keystone Heart is pleased to share the results from REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR) have been accepted for presentation in a late-breaking clinical science session at the upcoming Cardiovascular Research Foundation TCT Connect Meeting.
The REFLECT Phase II study is a prospective, randomized, multi-center study evaluating the safety and effectiveness of the TriGUARD 3™ Cerebral Embolic Protection Device during TAVR.
Introducing
| Presentation Title : | REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR) |
| Date and Time : | October 15th, 2020 at 11:20 am Eastern Time |
| Lecturer : | Jeffrey W. Moses, MD, Director, Interventional Cardiovascular Therapeutics and Professor of Medicine at New York-Presbyterian/Columbia University Medical Center; REFLECT Trial Study Chairman |
Join the session by registering at www.TCTConnect.com
The TriGUARD 3™ CEP Device is the only CE Marked cerebral embolic protection device designed to cover and protect all three cerebral vessels during transcatheter heart procedures
TCT Connect 2020
by TCT Connect 2020
246 people viewed this event.
TCT Connect 2020
Sorry, the comment form is closed at this time.